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Research
AbstrAct
Objectives To assess the long-term cost-effectiveness of 
a risk stratification pathway, compared with standard care, 
for detecting non-alcoholic fatty liver disease (NAFLD) in 
primary care.
Setting Primary care general practices in England.
Participants Adults who have been identified in primary 
care to have a risk factor for developing NAFLD, that is, 
type 2 diabetes without a history of excessive alcohol 
use.
Intervention A community-based pathway, which uses 
transient elastography and hepatologists to stratify 
patients at risk of NAFLD, has been implemented and 
demonstrated to be feasible (NCT02037867). Earlier 
identification could mean earlier treatments, referral to 
specialist and enrolment into surveillance programmes.
Design The impact of earlier detection and treatment 
with the risk stratification pathway on progression to 
later stages of liver disease was examined using decision 
modelling with Markov chains to estimate lifetime health 
and economic effects of the two comparators.
Data sources Data from a prospective cross-sectional 
feasibility study indicating risk stratification pathway and 
standard care diagnostic accuracies were combined with 
a Markov model that comprised the following states: no/
mild liver disease, significant liver disease, compensated 
cirrhosis, decompensated cirrhosis, hepatocellular 
carcinoma, liver transplant and death. The model data 
were chosen from up-to-date UK sources, published 
literature and an expert panel.
Outcome measure An incremental cost-effectiveness 
ratio (ICER) indicating cost per quality-adjusted life year 
(QALY) of the risk stratification pathway compared with 
standard care was estimated.
Results The risk stratification pathway was more effective 
than standard care and costs £2138 per QALY gained. The 
ICER was most sensitive to estimates of the rate of fibrosis 
progression and the effect of treatment on reducing 
this, and ranged from −£1895 to £7032/QALY. The risk 
stratification pathway demonstrated an 85% probability of 
cost-effectiveness at the UK willingness-to-pay threshold 
of £20 000/QALY.
Conclusions Implementation of a community-based risk 
stratification pathway is likely to be cost-effective.
Trial registration number NCT02037867,  ClinicalTrials. 
gov.
InTroducTIon
Non-alcoholic fatty liver disease (NAFLD) is 
the hepatic manifestation of the metabolic 
syndrome and is intimately linked with insulin 
resistance and abdominal obesity. It represents 
a spectrum from simple steatosis (found 
in most patients) through to non-alcoholic 
Strengths and limitations of this study
 ► Current algorithms for detecting non-alcoholic 
fatty liver disease are based in hospital, costly and 
associated with late diagnosis.
 ► A community-based risk stratification pathway, 
using non-invasive transient elastography to assess 
liver fibrosis, could fundamentally change detection 
of liver disease.
 ► This is the first economic evaluation of a risk 
stratification pathway that targets patients in a 
community setting who are at risk of developing 
non-alcoholic fatty liver disease.
 ► Data on fibrosis progression are limited to paired 
biopsy studies of specialist patients, which may 
not reflect the population within the model who are 
asymptomatic and have been specifically identified 
due to an underlying risk factor; trials that combine 
diagnostic and therapeutic intervention would 
be difficult or impossible to conduct due to the 
inadequacy and unethical aspects of performing 
liver biopsies in a community setting.
 ► Given the limitations of the data, we have examined 
carefully the potential consequences of assuming 
alternative values of input parameters in a series of 
one-way and multiway sensitivity analyses, testing 
the robustness of our results.
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steatohepatitis (NASH), the latter being associated with 
progressive liver fibrosis and cirrhosis.1 2 NAFLD is the 
most common liver disorder in the Western world3 4 and 
is the most frequent cause of abnormal liver function tests 
(LFTs) in the UK.5 Estimates of the prevalence of NAFLD 
in developed countries now exceed 30%,6 a figure likely 
to rise significantly given the increasing prevalence of 
overweight, obesity and type 2 diabetes. At present, in 
England 26% of adults are obese (body mass index (BMI) 
≥30 kg/m2),7 and 6% have type 2 diabetes.8 In these two 
populations NAFLD prevalence may be as high as 70%.9 
Importantly, patients with NAFLD are at increased risk 
of developing incident diabetes, cardiovascular-related 
and liver-related disease and premature death.10–13 Addi-
tionally, type 2 diabetes represents an important factor 
associated with more rapidly progressive fibrosis and 
adverse liver-related outcomes within NAFLD.14 15
Liver cirrhosis is responsible for over 1 million deaths 
per year worldwide,16 of which the increasing prevalence 
of NAFLD is an important contributing factor.4 As a result, 
in the UK, liver disease is now a public health priority,17 
with commentators highlighting the need for concerted 
action and the necessity of earlier detection and improved 
management within primary care.17–19 However, at present 
insensitive and poorly specific screening tests (LFTs) are 
used by primary care physicians and often performed 
opportunistically.
Poor sensitivity means a normal alanine transam-
inase (ALT) cannot necessarily exclude histological 
NASH, and therefore the risk of clinically significant liver 
disease.20 This lack of asymptomatic liver disease detec-
tion results in the failure to commence relevant lifestyle 
changes or medical management aimed at reducing 
the development of advanced liver fibrosis and decom-
pensated cirrhosis (the symptomatic stage of cirrhosis in 
light of liver failure, when 50% of patients receive their 
cirrhosis diagnosis21). Moreover, poor specificity22 poten-
tially leads to more invasive investigations, including 
repeated LFTs and specialist referral.
Non-invasive markers of liver fibrosis can change how 
we detect liver disease. Our recently published prospec-
tive study showed increased detection of significant liver 
disease and cirrhosis using mobile transient elastography 
(TE) in a community setting, compared with the current 
standard of care (SC) for investigating liver disease 
in primary care (both algorithms are shown in online 
supplementary appendix 1, figures 1.1 and 1.2.23 This 
pathway focuses on investigating patients with risk factors, 
including type 2 diabetes, rather than LFTs. Targeting 
specific high-risk populations, rather than screening the 
general population, has been supported by the European 
Association for the Study of the Liver (EASL) prac-
tice guidelines.24 However, the cost-effectiveness of this 
targeted screening approach is unknown.
Following published economic evaluation reporting 
criteria,25 we investigated the cost-effectiveness of this risk 
stratification pathway (RSP), compared with SC, from an 
NHS England perspective.
MeThods
The risk stratification and sc pathways
The RSP is a community-based diagnostic algorithm 
targeting patients identified to have a risk factor for devel-
oping chronic liver disease23 (see online supplementary 
appendix 1, figure 1.2). Briefly, patients identified with a 
risk factor for developing liver disease (hazardous alcohol 
use or type 2 diabetes) are invited to attend for a TE 
reading within the community. TE is an ultrasound-based 
imaging modality that provides an estimate of liver stiff-
ness through measurement of a kinetic wave, which the 
technology measures as it propagates through the liver 
stiffness. TE has been described extensively in the liter-
ature as an accurate predictor of liver fibrosis as seen on 
liver biopsy specimens.26 Following a patient’s TE and 
the results of any further investigations, a patient can be 
stratified to have no/mild liver disease, significant liver 
disease or compensated cirrhosis.
SC represents current referral pathways that rely on 
abnormal LFTs, specifically a raised ALT, or certain red 
flag features such as jaundice or significant transaminitis, 
to prompt referral to hospital for more specialist inves-
tigations and follow-up. Full details of the SC referral 
pathway are provided in online supplementary appendix 
1, figure 1.1. Patients who have been identified and strat-
ified by the RSP and SC pathways receive interventions 
aimed at reducing fibrosis progression. Currently, glita-
zone treatment and lifestyle intervention reflect best 
clinical practice.24
The study population
The study population reflected the patients who were 
identified in the feasibility study of two primary care prac-
tices in Rushcliffe, Nottingham (10 479 adult patients).23 
Within this population, the overall type 2 diabetes preva-
lence was 3.7% and obesity prevalence was 14.9% of those 
with recorded BMI measures. For the current economic 
modelling, subjects were identified using a Read diag-
nosis code indicating type 2 diabetes in the primary care 
physician’s database. Patients with a history of excessive 
alcohol use were excluded. The mean (SD) age of these 
patients (n=293) was 68.4 (12.6) years. The initial distri-
bution of patients between the three liver disease stages 
was assumed to reflect the distribution of patients strat-
ified by RSP in the feasibility study: 69% no/mild liver 
disease, 27% significant liver disease and 4% compen-
sated cirrhosis.
The decision-analytic model
The decision-analytic model (figure 1) was developed 
to describe the possible diagnosis treatment pathways 
of patients undergoing RSP or SC, using DATA TreeAge 
V.15 software. At the start of the model, the cohort with 
risk factors for NAFLD undergo either RSP or SC. Subse-
quent Markov model pathways are the same for RSP and 
SC. Health states are defined as no/mild disease (NMD, 
fibrosis stage 0 or 1), significant liver disease (SLD, fibrosis 
stage 2 or 3) and compensated cirrhosis (CC, fibrosis stage 
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4, reflecting Baveno stage I or II). The model estimates 
to what extent NMD, SLD and CC might be identified 
earlier using RSP compared with SC, and the impact that 
this earlier diagnosis has on treatment costs and patient 
outcomes.
Once a patient’s disease status is known, there is a prob-
ability that interventions will be implemented to reduce 
risk of progression. The probability of progressing to a 
subsequent stage of disease is assumed to be reduced if 
a patient is identified to be at risk of developing disease 
(NMD+), or diagnosed with SLD or CC (SLD+ and CC+), 
compared with a patient not identified to be at risk 
(NMD−), or has undiagnosed disease (SLD− and CC−). 
Separate Markov states reflect those patients who are 
identified/diagnosed through RSP or SC (ie, NMD+/
SLD+/CC+) and those who are not (ie, NMD−/SLD−/
CC−). States reflecting end-stage liver disease are decom-
pensated cirrhosis (DC), hepatocellular carcinoma 
(HCC), liver transplant (LT) and death. Transition prob-
abilities sections, together with table 1, provide the details 
of progression probabilities.
A stochastic probabilistic model was developed, where 
events occur with specified probabilities. The data inputs 
used to populate the model provide a measure of uncer-
tainty around the estimates. An annual cycle length with 
half-cycle correction, a lifetime horizon (until 100 years of 
age) and the UK Treasury recommended 3.5% discount 
rate for costs and outcomes were used.
data sources for transition probabilities, health status and 
resource use
An inclusive literature search was conducted through 
Medline, Embase and Web of Science for studies exam-
ining the natural history, treatment or resource use in 
managing NAFLD. References in English and limited 
to humans were included. After excluding duplicate 
records, potentially relevant studies were selected on title 
and abstract. Full texts of retrieved references were eval-
uated and reference lists were hand-searched. Due to a 
paucity of data in some areas, an expert advisory panel 
was convened to generate indicative estimates of transi-
tion probabilities and resource use.
Individual-patient data from the feasibility study23 were 
used to generate input parameters related to RSP and SC 
target population characteristics and diagnostic effective-
ness.
Transition probabilities
Liver disease progression
There are little data quantifying progression rates through 
stages of NAFLD. It was necessary to identify and synthe-
sise data from multiple sources. Transition probabilities 
for cirrhosis were taken from up-to-date UK sources that 
reflected the characteristics of the NAFLD population in 
the model.27 A published meta-analysis estimating fibrosis 
progression rate was used to generate transition prob-
abilities for NMD and SLD states.28 An expert panel of 
UK hepatologists was convened to generate indicative 
estimates where no data were available (see table 1 for 
transition probabilities and sources; elicitation methods 
provided in online supplementary appendix 2, figure 2.1 
and table 2.1).
Effect of implementing RSP on disease progression
The impact of implementing the RSP on health outcomes 
and costs, compared with SC, occurs as a consequence 
of (1) increased identification rate of patients at risk 
of NAFLD by RSP compared with SC, and (2) effect of 
earlier identification, diagnosis and treatment on disease 
progression.
1. Identification rates of patients at risk of NAFLD 
by RSP and SC were derived from a cross-sectional 
feasibility study.23 In RSP, the probability of 
identifying/detecting NMD/SLD/CC cases was 
estimated as the proportion of patients who accepted 
the invitation to undergo RSP in the feasibility study 
(73.7%=216/293), assuming that (1) RSP gave the 
true population prevalence: since there was no gold 
standard diagnostic pathway to approximate true 
population prevalence, a patient participating in 
the RSP was accurately identified/diagnosed and 
placed into the correct health state NMD/SLD/
CC with no false-positives or false-negatives; (2) the 
proportion of those in each disease state (NMD/
SLD/CC) was the same for those who did and did 
not participate, as there was nothing to suggest that 
patients with asymptomatic liver disease were more 
Figure 1 Decision tree and Markov model for the economic 
evaluation of risk stratification pathway in non-alcoholic 
fatty liver disease. Markov model states: NMD, no/mild 
disease: a patient can be identified (NMD+) or not identified 
(NMD−) to be at risk of developing disease; SLD, significant 
liver disease: a patient can be diagnosed (SLD+) or not 
(SLD−); CC, compensated cirrhosis: a patient can be 
diagnosed (CC+) or not (CC−); DC, decompensated cirrhosis; 
HCC, hepatocellular carcinoma; LT, liver transplant. Death 
possible from every state.
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or less likely to participate in the RSP compared 
with those without; and (3) a patient’s decision to 
participate in the RSP in a given year was independent 
of a patient’s participation in the previous years. In 
SC, the probability of identifying NMD, SLD and 
CC was estimated from the percentage of patients in 
the feasibility study who would be identified if only 
SC was available, assuming that (i) the number of 
patients with raised ALT who participated in the RSP 
reflected those who would be identified through the 
SC pathway, (ii) patients who did not participate in 
the RSP would also not have attended their primary 
care practices for management under SC, and that 
(iii) there were no false-positives for SC. Therefore, 
analysing ALT levels of 216 patients who participated 
in the RSP, the probability of identifying NMD, SLD 
and CC in SC was estimated to be 2.0%, 16.5% and 
8.2%, respectively.
2. The effect of earlier identification, diagnosis and 
treatment on disease progression was captured by 
estimating the reduction of transition probabilities 
for NMD+/SLD+/CC+ states, compared with NMD−/
SLD−/CC− states. No published data were found to 
support estimation of this effect for NMD, SLD and 
CC health states. In the case of fibrosis progression 
(NMD to SLD and SLD to CC), an individual-patient 
data set from an randomised controlled trial (RCT) 
that studied the histological effect of rosiglitazone 
in an NAFLD population (Fatty Liver Improvement 
with Rosiglitazone Therapy trial29) was used to 
calculate the relative risks for reduction of fibrosis 
progression. Sixty-three patients in the trial (32% 
had type 2 diabetes) had a liver biopsy at baseline and 
1 year. The intervention group was offered advice on 
lifestyle modifications and treated with rosiglitazone. 
The placebo group was offered advice about lifestyle 
modifications only. The intervention group was 
assumed to be equivalent to the identified/detected 
arm within our model. As no specific treatment was 
given to the placebo group, it was assumed that the 
fibrosis progression observed in this group would be 
equivalent to that seen in the unidentified/undetected 
arm within our model. In the case of transition 
probabilities for CC, expert opinion was employed 
to approximate the effect of diagnosing and treating 
cirrhosis on disease progression and mortality. (The 
resultant relative risks and transition probabilities for 
undiagnosed (NMD−/SLD−/CC−) and diagnosed 
(NMD+/SLD+/CC+) states are summarised in 
table 1; details are in online supplementary appendix 
2, tables 2.2a, 2.2b, 2.3 and 2.4).
utilities
No studies reporting utilities for NAFLD health states 
were found. Based on expert opinion (ING, DJH, RH), 
and given that people in health states NMD, SLD, CC− 
generally have asymptomatic NAFLD, health-related 
quality-of-life (QoL) data for NMD, SLD and CC− were 
approximated using QoL data from type 2 diabetes. For 
CC+, the utility decrement of 0.1 was assumed to capture 
psychological effects of diagnosis; this was not added to 
NMD+ and SLD+ utilities since identification of these 
fibrosis stages indicates risk of developing cirrhosis and 
advanced liver disease in the future and is not considered 
as disease diagnosis. Data on QoL obtained using the stan-
dard EuroQol five-dimension three-level questionnaire 
with societal weights,30 reported in the Health Survey for 
England,31 and results of the feasibility study23 were used 
to calculate age-dependent utility for NMD, SLD and CC 
health states. Specifically, the regression coefficients for 
age, sex, BMI and hypertension estimated for the general 
population,31 together with data on demographics and 
prevalence of obesity and hypertension in the feasi-
bility study cohort (47.4% patients with BMI >30, 63.5% 
with hypertension),23 were applied to calculate utilities 
reflecting the model health states for the target popula-
tion. In the absence of data for DC, HCC and LT health 
states in NAFLD, utilities were taken from a study of 
patients with hepatitis C infection.32 It was assumed that 
having a different cause would not affect the health state 
valuation in these states (see table 2 for utility data and 
online supplementary appendix 3, table 3.1 for a detailed 
summary).
costs
For patients identified to be at risk of, or diagnosed 
with, chronic liver disease, costs for the NMD+/SLD+/
CC+ health states differ between the RSP and SC arms 
due to a difference in the diagnostic investigations and 
therapeutic interventions delivered. It was assumed that 
patients who are unidentified or undiagnosed (NMD−/
SLD−/CC−) accrue no costs in either arm. Resource use 
for each health state was estimated based on published 
literature, UK local and national guidelines and inter-
national clinical practice guidelines from EASL and 
the American Association for the Study of Liver Disease. 
These estimates were checked for validity with the expert 
panel.
Most unit costs used were derived from NHS refer-
ence costs, Personal Social Services Unit and NHS pay 
scales.33 34 Where a cost could not be identified, a literature 
search was conducted or local finance departments were 
contacted. All costs were inflated to the 2013/2014 finan-
cial year.34 Where a range of costs was available, minimum 
and maximum costs were reported and included in the 
economic modelling (see table 2; detailed costs are in 
online supplementary appendix 4, tables 4.1–4.9).
cost-effectiveness analysis
The analysis generated the cost per extra quality-adjusted 
life year (QALY) gained by the RSP compared with SC. 
The difference in patient outcome and costs between the 
RSP and SC was generated. Deterministic and probabi-
listic incremental economic analyses were carried out. 
The incremental cost-effectiveness ratio (ICER), cost per 
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extra QALY generated by RSP over SC, was calculated 
using the following equation:
 ICER = (CostRSP − CostSC)/(QALYRSP −QALYSC) 
Where available, data were specified as distributions to 
fully incorporate the uncertainty around parameter values 
for probabilistic analysis (details of distribution used are 
provided in tables 1 and 2). The analysis was run with 
5000 iterations, using Monte Carlo simulation to obtain 
point estimates and ranges of QALYs and costs gener-
ated by RSP or SC, and ICER distributions. We report the 
proportion of ICER estimates in each of the four quad-
rants of the cost-effectiveness plane. Cost-effectiveness 
acceptability curves35 were constructed to express the 
probability that RSP is cost-effective as a function of the 
decision-maker’s ceiling ICER (λ) for base-case, sensitivity 
and scenario analyses.36 The currently accepted National 
Institute for Health and Care Excellence threshold of 
£20 000 per QALY gained was used to assess probability of 
cost-effectiveness.37
Many model parameters were subject to one-way sensi-
tivity analysis (OSA) to determine key drivers of the 
model results. Ranges of input parameters were based 
on alternative values identified in the literature, the 
upper and lower limits of CIs of base-case estimates, or 
were arbitrary (employing expert opinion where appro-
priate). Intervals for deterministic OSA were chosen 
conservatively to incorporate maximal level of uncer-
tainty around point estimates. Incremental costs, QALYs 
and ICERs were calculated for extreme values of the 
parameters, keeping all other model inputs unchanged. 
A tornado diagram was presented for the parameters 
with the highest impact on the ICER, plotting ranges 
for ICERs for these parameters in descending order 
(see online supplementary appendix 5, table 5.1 for 
further detail).
Multiway sensitivity analyses were conducted: (1) 
assuming no effect of both fibrosis and cirrhosis detec-
tion (treatment) on the progression of liver disease and 
no utility decrement for cirrhosis detection, to check 
internal validity of the model and estimate lifetime incre-
mental cost of RSP, compared with SC (cost-minimisation 
analysis); (2) assuming no effect of fibrosis detection and 
treatment (on progression from NMD to SLD and from 
SLD to CC) and base-case effect of cirrhosis diagnosis 
and treatment on the natural history of disease; and (3) 
assuming no effect of cirrhosis diagnosis and treatment 
(on progression and mortality from CC) and base-case 
effect of fibrosis detection on the natural history of 
disease, where scenarios (2) and (3) were calculated with 
and without utility decrement for cirrhosis detection.
resulTs
Base-case analysis
Deterministic cost-effectiveness analysis derived a mean 
lifetime cost per patient of £9017 for RSP and £8505 for 
SC. The mean QALYs generated was 8.49 for RSP and 
8.25 for SC. Incremental cost was £512 and incremental 
QALY was 0.24, providing an ICER of £2138 per extra 
QALY gained for RSP compared with SC (table 3).
In the probabilistic cost-effectiveness analysis, the mean 
lifetime cost per patient (2.5% and 97.5% percentiles) 
was £10 307 (£3811 and £20 442) and £10 082 (£3494 and 
£20 793) for RSP and SC, respectively. The mean QALYs 
generated per patient (2.5% and 97.5% percentiles) were 
Table 2 Annual costs* and utilities for the model states
Cost (range), in £ Utility†
Health state Pathway First year Subsequent year Utility value Source
NMD+ RSP 183 158 0.88–0.91 ref 23 31
SC 1223 65
NMD− RSP/SC 0 0
SLD+ RSP 1219 363 0.88–0.91 ref 23 31
SC 1223 368
SLD− RSP/SC 0 0
CC+ RSP 1721 (1651–1791) 921 (887–956) 0.78–0.81 ref 23 31 50
SC 1725 (1656–1795) 884 (850–919)
CC− RSP/SC 0 0 0.88–0.91 ref 23 31
DC 6672 (4221–9123) 7706 (5525–9887) 0.66 (95% CI 0.46 to 0.86) ref 32
HCC 19 414 (19 151–19 678) 18 172 (17 909–18 436) 0.65 (95% CI 0.44 to 0.86)
Transplant 89 282 (56 301–184 574) 20 687 (15 549–25 452) 0.69 (95% CI 0.62 to 0.77)
*The details with data sources for costs are in online supplementary appendix 4. We used triangular or uniform distribution to encompass 
uncertainty around expert opinions, where triangular distribution was used in the cases in which the most likely estimate was identified.
†We used beta distribution for DC, HCC and transplant utilities; normal distribution was used for coefficients in the regression equation used 
to calculate utilities for NMD, SLD and CC states.
CC, compensated cirrhosis; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; NMD, no/mild disease; RSP, risk stratification 
pathway; SC, standard care; SLD, significant liver disease.
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7.93 (2.80 and 11.09) for RSP and 7.72 (2.78 and 10.67) 
for SC. Incremental cost and QALYs were £225 (−2699 and 
2856) and 0.21 (−0.1 and 0.65), respectively. The ICER 
(2.5% and 97.5% percentiles) was −£1010 (−£40 583 and 
£50 023). There was a 37% probability that RSP domi-
nated SC and 85% probability that RSP was cost-effective 
at the UK willingness-to-pay threshold of £20 000/QALY 
(table 3 and figure 2).
one-way sensitivity analyses
Figure 3 summarises the results of the OSA. The two 
parameters with the highest impact on the ICER were (1) 
altering the rate of fibrosis progression, resulting in an 
ICER ranging from £928 to £7032 per QALY, (2) altering 
the effect of treatment on the rate of progression between 
NMD to SLD, and SLD to CC from the largest to no reduc-
tion (see table 2.4a,b in online supplementary appendix 
2), resulting in an ICER ranging from −£1895 to £5969 
per QALY gained (see online supplementary appendix 
5, table 5.1 and figures 5.1–5.3 for detailed assumptions 
and the results of all OSAs conducted).
Multiway sensitivity analyses
When detection and treatment of fibrosis and cirrhosis 
are assumed to have no effect on the rate of disease 
progression and mortality (transition probabilities from 
NMD+, SLD+ and CC+ are the same as those from NMD−, 
SLD− and CC−, respectively), RSP cost about £2000 more 
over a lifetime horizon compared with SC due to the 
increased diagnostic costs over subsequent years (table 3, 
scenario 1).
When it was assumed that detecting and treating 
patients with fibrosis have no effect on disease progres-
sion (transition probabilities from NMD+ and SLD+ are 
the same as those from NMD− and SLD−, respectively), 
the ICER increased to £18 130/QALY (table 3, scenario 
2b).
When it was assumed that diagnosing or treating 
patients with CC has no effect on disease progression and 
mortality, the ICER increased to £7669/QALY (table 3, 
scenario 3b).
Table 3 Cost-effectiveness analysis of RSP versus SC: base-case scenario, probabilistic and multiway sensitivity analyses
Deterministic results, mean
Cost (in £)*
Incremental cost (£),
RSP versus SC QALY
Incremental 
QALY,
RSP versus SC ICER (£/QALY)
RSP 9017 512 8.49 0.24 2138
SC 8505 8.25
Probabilistic sensitivity analysis results, mean (2.5% and 97.5% percentiles)
RSP 10 307 (3811 and 20 442) 225 (−2699 and 2856) 7.93 (2.80 and 11.09) 0.21 (−0.1 and 
0.65)
−1010* (−40 583 and 
50 023)SC 10 082 (3494 and 20 793) 7.72 (2.78 and 10.67)
Multiway sensitivity analysis: scenario 1†
RSP 10 849 1936 8.36 0 n.a.
SC 8913 8.36
Multiway sensitivity analysis: scenario 2a†
RSP 10 913 1715 8.31 0.16 10 634
SC 9197 8.15
Multiway sensitivity analysis: scenario 2b†
RSP 10 913 1715 8.23 0.09 18 130
SC 9197 8.14
Multiway sensitivity analysis: scenario 3a†
RSP 8953 708 8.59 0.14 5106
SC 8245 8.45
Multiway sensitivity analysis: scenario 3b†
RSP 8953 708 8.53 0.09 7669
SC 8245 8.44
*RSP dominated by SC (NW quadrant): 5.8%; SC dominated by RSP (SE quadrant): 37.1%; NE quadrant: 56.3%; SW quadrant: 1.0%.
†Assumptions on NAFLD progression: (1) no cirrhosis and fibrosis detection effect on disease progression, (2) no fibrosis detection effect on 
disease progression, (3) no cirrhosis detection effect on disease progression. Assumptions on utility decrement for cirrhosis detection: (a) no 
utility decrement and (b) utility decrement (as in base case).
ICER, incremental cost-effectiveness ratio; n.a., not applicable; NAFLD, non-alcoholic fatty liver disease; NE, north east; NW, north west; 
QALY, quality-adjusted life year; RSP, risk stratification pathway; SC, standard care; SE, south east; SW, south west.
group.bmj.com on July 10, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
8 Tanajewski L, et al. BMJ Open 2017;7:e015659. doi:10.1136/bmjopen-2016-015659
Open Access 
Figure 2 Probabilistic sensitivity analysis: cost-effectiveness plane and cost-effectiveness acceptability curve for risk 
stratification pathway versus standard care.
Figure 3 Tornado diagram. CC, compensated cirrhosis; CCI, compensated cirrhosis Baveno stage I; CCII, compensated 
cirrhosis Baveno stage II; DC, decompensated cirrhosis; DCIII, decompensated cirrhosis Baveno stage III; HCC, hepatocellular 
carcinoma; ICER, incremental cost-effectiveness ratio; NMD, no/mild disease; QALY, quality-adjusted life year; RR, relative risk; 
RSP, risk stratification pathway; SLD, significant liver disease. 
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dIscussIon
Principal findings
This study showed that implementation of RSP in the 
community is likely to be cost-effective according to UK 
cost-per-QALY thresholds, even in the presence of signifi-
cant uncertainty around estimates.
strengths and weaknesses
This is the first economic evaluation of an RSP to identify 
people at risk of developing NAFLD based in a commu-
nity setting. Previous cost-effectiveness analyses have 
used a simulated cohort of patients already referred to 
hospital following repeated liver enzyme abnormalities, 
specifically a raised ALT.38 39 With this approach, a large 
proportion of patients with NASH but normal LFTs would 
be overlooked.20 Targeting patients with a risk factor in 
the community enables more patients to be stratified and 
removes the reliance on LFTs. The model is also based on 
observed patient data from a community setting in the 
UK to whom RSP was offered.23 In the absence of data 
on the true prevalence of NAFLD in a community popu-
lation, this approach provides realistic estimates for the 
probabilities of detecting patients at risk using RSP or 
current referral algorithms.
The results of this economic analysis have been based 
on conservative assumptions; therefore, our estimates 
of cost-effectiveness represent a pessimistic scenario in 
which the health and economic benefits of replacing 
SC with RSP are likely to be underestimated. Due to the 
complexity of the model, other wider health benefits have 
also not been included. Steatosis within the liver results in 
hyperinsulinaemia and can precede the development of 
diabetes, hypertension and dyslipidemia.13 Consequently, 
this has also been associated with an increased prevalence 
of cardiovascular disease and mortality.40 Given that RSP, 
if implemented, could also reduce the incidence of these 
sequelae by identifying patients at risk and allowing the 
opportunity for these complications to be screened for 
and treated, the true impact may be underestimated.
Limitations of our model are primarily due to the lack 
of appropriate data available. Data on fibrosis progres-
sion are limited to paired biopsy studies of secondary 
care patients,28 which may not reflect the population 
within the model who are asymptomatic and have been 
specifically identified due to an underlying risk factor. 
Very few studies have researched NAFLD in a community 
population or evaluated the progression of early-stage 
liver disease,5 28 41 42 and no studies were identified on 
the QoL for patients with NAFLD. In early-stage liver 
disease, available QoL data are limited to patients with 
viral hepatitis43; therefore, utility scores have been used 
from populations known to have an underlying risk factor 
for NAFLD, that is, type 2 diabetes, as these reflect health 
states of NAFLD population better than utilities in viral 
hepatitis. Although this is likely to be a good surrogate, 
the validity of this assumption is unclear. For end-stage 
liver disease, QoL data were taken from studies of hepa-
titis C cohorts. It was assumed that QoL would be similar 
despite the different aetiologies, but again the validity of 
this assumption is unclear.
The sensitivity and specificity of TE within a primary 
care setting are currently unknown, as there are prac-
tical and ethical aspects of performing liver biopsies in a 
community setting; this represents a limitation. We have 
addressed this by extrapolating thresholds with a high 
negative predictive value (>93%) and confirming all cases 
with cirrhosis with additional tests including liver biopsy 
as outlined in our previous publication.23
Although we believe our findings to be generalisable 
to liver disease screening in other regions of the UK, we 
acknowledge two points in particular that may alter data 
input to the base-case analysis of the Markov model. First, 
the obesity and type 2 diabetes prevalence in the overall 
primary care population in the feasibility study (15% and 
4%, respectively) is lower than overall expected UK levels. 
Second, the feasibility pilot-studied patients with type 2 
diabetes, rather than all metabolic syndrome risk factors. 
This means that we are likely to have identified those 
patients with NAFLD most at risk of SLD and cirrhosis; 
study of all NAFLD risk factors may therefore alter the 
starting percentages of SLD and CC within the Markov 
model. Nonetheless, the one-way sensitivity analyses have 
demonstrated that, irrespective of uncertainties in the 
data, the conclusions of this economic evaluation are 
robust.
clinical implications
A major challenge with chronic liver injury is the absence of 
symptoms until decompensation occurs, which is associated 
with a high mortality21 and increased healthcare utilisation. 
Thus, if the burden of liver disease is to be reduced, it can 
only be achieved via the reduction in aetiological exposures 
(which are rising not falling), or by targeting the asymptom-
atic via screening or case-finding strategies.
The RSP we have investigated offers an opportunity to 
integrate liver-specific interventions within diabetes care 
models in the community. This does not currently happen 
in a systematic fashion, both because of a lack of recogni-
tion of liver disease within diabetes and the lack hitherto of 
available tools to identify early liver disease outside specialist 
care settings. The implementation of a pathway such as ours 
which uses pioglitazone as the treatment of choice could 
have implications for liver-related morbidity and mortality 
and potentially may reduce cardiovascular and metabolic 
clinical outcomes.44 45 For patients, there are additional 
benefits not captured by this economic model, including 
the convenience of obtaining diagnostic tests in a timely 
manner and at a convenient location.
Finding additional resources to implement new pathways 
represents a challenge because the benefits are long term 
and investment is required in the short term. However, 
redefining how we use current diagnostic tests, including 
low-cost but high-volume LFTs, is a key strategy. A popula-
tion-based observational cohort study of patients in Tayside 
Scotland identified 95 977 patients who had incidental LFTs 
requested for no obvious liver disease; only 0.5% had liver 
group.bmj.com on July 10, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
10 Tanajewski L, et al. BMJ Open 2017;7:e015659. doi:10.1136/bmjopen-2016-015659
Open Access 
disease 2 years later.46 The Birmingham and Lambeth Liver 
Evaluation Testing Strategies (BALLETS) study found that 
38% of abnormal community LFTs had been requested 
as part of routine testing in chronic disease management, 
including diabetes, hypertension and cardiovascular 
disease, yet in almost half of these cases no underlying liver 
disease was subsequently found.5 Funding for the approach 
we propose could be derived from savings on the use of 
these ineffective tests.
The ability to intervene earlier in the natural history of 
liver disease depends on the idea that hepatic fibrosis is 
reversible or can at least have its progression retarded by 
intervention.47 48 Should the ideas we promote here be 
adopted, we believe that the identification of large numbers 
of patients with early liver disease will greatly facilitate the 
development of better therapies for their condition. The 
sensitivity analyses for our economic model shows that as 
more effective treatments emerge they will further improve 
the ICER by reducing progression from (1) mild disease to 
SLD or (2) SLD to cirrhosis, or both.
Future perspectives
The economic model highlights gaps in current knowl-
edge that need to be addressed. These include the 
long-term clinical outcomes of liver disease, identified 
specifically by non-invasive markers in the community. 
Secondary care studies suggest excellent prognostic 
performance of TE in NAFLD,49 and replication of these 
results from community cohorts is awaited.
A future RCT that combines diagnostic and thera-
peutic intervention would be the gold standard study 
design. However, the difficulty in defining short-term 
outcomes, due to the inadequacy and unethical aspects 
of performing liver biopsies in a community setting, in 
conjunction with the very prolonged wait required for 
hard clinical outcomes in liver disease, means that such 
a trial could not report for many years. Thus, this study 
provides valuable data during this hiatus when deaths 
from chronic liver disease continue to rise worldwide.
conclusIons
The rising tide of liver disease due to NAFLD and the 
lack of established strategies to reliably detect and treat 
it at an early stage present a clear need for new ways of 
working within clinical hepatology. We believe that the 
RSP we are studying is both feasible to implement and 
is cost-effective.
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